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ABSTRACT
Background: Vitamin K occurs in the diet as phylloquinone
and menaquinones. Observational studies have shown that both
phylloquinone and menaquinone intake might reduce cardiovascular
disease (CVD) risk. However, the effect of vitamin K on vascular
calcification is unknown.
Objectives: The aim of this study was to assess if menaquinone sup-
plementation, compared to placebo, decreases vascular calcification
in people with type 2 diabetes and known CVD.
Methods: In this double-blind, randomized, placebo-controlled trial,
we randomly assigned men and women with type 2 diabetes
and CVD to 360 μg/d menaquinone-7 (MK-7) or placebo for
6 mo. Femoral arterial calcification at baseline and 6 mo was
measured with 18sodium fluoride positron emission tomography
(18F-NaF PET) scans as target-to-background ratios (TBRs), a
promising technique to detect active calcification. Calcification mass
on conventional computed tomography (CT) scan was measured
as secondary outcome. Dephosphorylated–uncarboxylated matrix
Gla protein (dp-ucMGP) concentrations were measured to assess
compliance. Linear regression analyses were performed with either
TBR or CT calcification at follow-up as the dependent variable,
and treatment and baseline TBR or CT calcification as independent
variables.
Results: We randomly assigned 35 patients to the MK-7 group (33
completed follow-up) and 33 to the placebo group (27 completed
follow-up). After the 6-mo intervention, TBR tended to increase
in the MK-7 group compared with placebo (0.25; 95% CI: −0.02,
0.51; P = 0.06), although this was not significant. Log-transformed
CT calcification mass did not increase in the intervention group
compared with placebo (0.50; 95% CI: −0.23, 1.36; P= 0.18). MK-
7 supplementation significantly reduced dp-ucMGP compared with
placebo (−205.6 pmol/L; 95% CI: −255.8, −155.3 pmol/L). No
adverse events were reported.
Conclusion: MK-7 supplementation tended to increase active
calcification measured with 18F-NaF PET activity compared with
placebo, but no effect was found on conventional CT. Additional
research investigating the interpretation of 18F-NaF PET activity
is necessary. This trial was registered at clinicaltrials.gov as
NCT02839044. Am J Clin Nutr 2019;110:883–890.
Keywords: menaquinone-7, vitamin K, vascular calcification,
cardiovascular disease, diabetes
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Introduction
Vascular calcification is associated with a 3- to 4-fold
increased risk of cardiovascular events (1, 2). In the past,
vascular calcification was viewed as a passive process of calcium
deposition, but evidence has shown that vascular calcification
is an active process regulated by stimulators and inhibitors
(3). Matrix Gla protein (MGP), a vitamin K-dependent protein,
functions as an inhibitor of vascular calcification (4). This
function of MGP was first shown in MGP knockout mice, which
resulted in initiation and progression of vascular calcification
(4). Multiple observational studies have since shown that low
levels of inactive MGP, dephosphorylated–uncarboxylated MGP
(dp-ucMGP), are associated with less vascular calcification and
reduced cardiovascular disease (CVD) risk (5). Vitamin K is
suggested to reduce vascular calcification and risk of CVD.
Vitamin K is fat-soluble and occurs in 2 different forms,
phylloquinone (vitamin K-1) and menaquinones (vitamin K-2).
Phylloquinone is mainly derived from green leafy vegetables,
whereas menaquinones mainly occur in fermented animal
products such as cheese and meat (6). Phylloquinone and
menaquinones have the same chemical structure but differ in the
length and saturation degree of the side chain (7). Menaquinones
have a longer half-life and a higher bioavailability.
Multiple observational studies have shown a reduced CVD
risk with high vitamin K intake (5), although the evidence is not
conclusive. To date, 2 studies have investigated the effect of phyl-
loquinone supplementation on vascular calcification and have
shown reduced progression in older men and women (8) and in
chronic kidney disease patients (9). The effect of menaquinones
on vascular calcification has not been investigated, although 2
intervention studies have shown a reduced vascular stiffness
after menaquinone supplementation (10, 11), and another study
did not find an effect of menaquinone supplementation on
vascular stiffness or other markers of vascular health (12).
None of the trials investigated the effect of vitamin K and
vascular calcifications in people with type 2 diabetes, although
vascular calcification is prevalent in ∼70% of people with
type 2 diabetes (1). Finally, vascular calcification is an active
process, but none of the studies measured the active vascular
calcification. 18Sodium fluoride positron emission tomography
(18F-NaF PET) is a promising technique to detect early changes in
active vascular calcification before calcifications become visible
by computed tomography (CT) (13). Therefore, this double-
blind, randomized placebo-controlled trial aimed to investigate
the effect of 6 mo of menaquinone-7 (MK-7) supplementation
on active vascular calcification, measured by 18F-NaF PET
activity, in people with type 2 diabetes and a history o
f CVD.
Methods
Study design and study population
This study is a double-blind, randomized placebo-controlled
trial. Participants were recruited through a pre-existing diabetes
cohort study (Utrecht participants only) (14), a Julius Center
database of subjects who are interested in participating in studies,
and via outpatient clinics of the University Medical Center
Utrecht and Diakonessenhuis Utrecht. Participants who met
the following criteria were included in the study: men and
women aged >40 y with diagnosed type 2 diabetes and pre-
existing CVD, because vascular calcification is highly prevalent
in this patient group, and an estimated glomerular filtration rate
(eGFR) >30. Exclusion criteria were vitamin K antagonist use,
use of (multi)vitamins with vitamin K, unwillingness to stop
vitamin K use before randomization, and known coagulation
problems such as deep vein thrombosis. All participants gave
written informed consent prior to participation. This trial was
approved by the institutional review board of the University
Medical Center Utrecht and registered at clinicaltrials.gov as as
NCT02839044.
Intervention
Participants were randomly assigned to 360 μg MK-7 daily
or a placebo supplement for 6 mo. Participants received daily
2 tablets of MK-7 (Nattopharma) or placebo (Legosan), which
were similar in taste and appearance. Participants were asked
to take the tablets with their evening meal. At the start and
at the end of the study, MK-7 and placebo tablets were
measured for MK-7 content to assess the stability of the
tablets (Maastricht University). HPLC, reversed-phase C-18
column, and fluorometric after post column electrochemical
reduction were used to determine the free vitamin K-2 (MK-7)
concentration. During the entire study, the MK-7 content was
stable, with 262 μgMK-7 at the start and 223 μgMK-7 at the end
of the study. Because this is not a standard biomarker test, this
might be an overestimation. Participants returned their leftover
tablets, and we calculated the compliance as the number of tablets
actually taken divided by the number of tablets that should have
been taken. dp-ucMGP serves as a marker for vitamin K status,
where low dp-ucMGP concentrations represent long-term high
vitamin K intake (15). Therefore, dp-ucMGP was measured at
baseline, 3 mo, and 6 mo to assess whether participants were
compliant to the treatment. dp-ucMGP was measured with the
sandwich ELISA method using the IDS Automated Analyser
IDS-iSYS InaKtif MGP assay (Maastricht University).
Participants were randomly assigned in a 1:1 ratio, stratified
for sex, performed by the data management department through
a computerized method. A list of numbers was created, and the
researcher only received a medication number. During the study,
the randomization code was kept at the data management and
pharmacy departments.
Study endpoints
The primary outcome was active vascular calcification,
measured as femoral arterial wall 18F-NaF PET activity measured
at baseline and 6 mo. 18F-NaF PET activity is promising
for detecting early changes in active deposition of vascular
calcification before calcifications become visible on CT, due to
the binding of the tracer to hydroxyapatite, thereby enabling
the detection of microcalcifications. Therefore, this method is
suitable to detect changes in active calcification during a 6-mo
intervention period. 18F-NaF PET activity is prevalent in the
femoral arteries because medial calcification mostly resembles
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evaluated without activity spillover from adjacent bones, in
contrast to abdominal aortic uptake (16).
18F-NaF PET CT scans were conducted at baseline and
after 6 mo on a Siemens Biograph 40 scanner (Siemens
Healthcare). Ninety minutes before imaging, participants re-
ceived an intravenous injection of 2.0 MBq/kg 18F-NaF, with
a maximum dosage of 200 MBq. The primary outcome was
the target-to-background ratio (TBR) measured in the femoral
artery.
The maximal standardized uptake value (SUVmax) was mea-
sured in the left and right femoral artery, from the bifurcation
of the femoral artery to the femur condyles (IntelliSpace Portal
v8.0; Philips Healthcare). Slice thickness was 5 mm, with a slice
interval of 4 mm. The mean of the SUVmax of the left and right
femoral artery was calculated (mean number of 47 measurements
per patient). Second, the blood pool was determined in the
superior vena cava on consecutive slices starting at the aortic
arch. Three measurements of the mean standardized uptake
value (SUVmean) were performed and an average was used. The
femoral TBR was calculated by the SUVmax in the femoral artery
divided by the SUVmean in the vena cava. Vascular calcification
on conventional CT images was measured as a secondary
outcome. Calcification in both left and right femoral artery
was measured using in-house–developed software (iX Viewer;
Image Sciences Institute), using a threshold of 130 Hounsfield
units for calcium. Calcification mass score was computed as
the product of the volume of the lesion (in milliliters) and
the mean attenuation (in Hounsfield units) of the lesion (17).
Similar to the PET/CT images, we measured calcification from
the bifurcation of the femoral artery to the femur condyles. Both
TBR and arterial calcification measurements were performed by
1 investigator (RvA), blinded for treatment and patient character-
istics. Three investigators, blinded for all characteristics, assessed
10 randomly selected participants (5 baseline and 5 follow-
up measurements) to calculate the interobserver reliability for
TBR measurements, and 20 randomly selected participants for
calcification mass (10 baseline and 10 follow-up measurements).
The intraclass correlation for the interobserver reliability was
0.98 (95% CI: 0.94, 0.99) for TBR measurements and 0.998
(95% CI: 0.995, 0.999) for calcification mass using conventional
CT imaging.
Other measurements
Participants visited the University Medical Center Utrecht at
baseline and after 3 and 6 mo. During these visits, lifestyle
questionnaires were obtained, including disease history, medica-
tion use, and smoking habits. During each visit, anthropometric
measurements including height, weight, and waist and hip
circumference were performed twice, and a mean value was
calculated. Ankle–brachial index (ABI), a measurement of
arterial stiffness, was measured at baseline. ABIs were calculated
by dividing the highest average arm systolic blood pressure by
the highest of the ankle pressures of that leg. Blood pressure
was measured twice in the sitting position using an automated
oscillomat (Omron HEM-907). Nonfasting blood samples were
drawn, and glycated hemoglobin, creatinine, and lipid levels
were measured. eGFR was calculated using the MDRD formula.
Finally, participants were asked to complete a 3-d food record
to obtain the dietary vitamin K intake. The food record included
3 nonconsecutive days, including 2 weekdays and 1 weekend
day, and consisted of a prespecified format for breakfast, lunch,
dinner, and snacks. The food records were analyzed using Evry
(Ensemble BV), based on the Dutch national food composition
table (2013) (18) and a previously described vitamin K food
content database (19). The energy-adjusted intakes of total
vitamin K, phylloquinone, and menaquinones were calculated
using the residual method.
Statistical analysis
The sample size was calculated based on a previous study
including 18F-NaF PET CT, showing a mean TBR of 1.96 (16).
With a power of 80%, a 2-sided α of 5%, an SD of the difference
in TBR between baseline and follow-up of 0.41, and a 15%
dropout rate, 70 participants were required to detect a 15%
difference in TBR. A 15% difference was also found in previous
studies investigating the effect of vitamin K on coronary artery
calcification (8, 9).
Baseline characteristics were described as percentages,
means ± SDs, or medians (IQRs) as appropriate per treatment
arm, and clinically relevant baseline differences between treat-
ment arms were visually assessed. The primary endpoint was
TBR, and log-transformed calcification mass was included as
a secondary endpoint. Absolute differences between baseline
and follow-up were calculated. Linear regression analyses were
performed with the follow-up calcification measurement as
outcome and treatment and baseline calcification measurement
as independent variables (e.g., TBR at follow-up = interven-
tion + TBR at baseline). We used linear regression models
because analyzing change scores does not appropriately control
baseline imbalances (20). Because baseline CT calcification
mass, phylloquinone intake, and a low ABI differed between
the intervention and placebo groups at baseline, we adjusted
for these variables in a secondary analysis. Due to the baseline
difference in calcification mass between treatment arms and
the strong predictive value of baseline calcification mass on
progression of calcification mass (21, 22), we assessed the
correlation between baseline and difference between baseline
and follow-up measurements for calcification mass and TBR
using Spearman’s correlation coefficients. Because baseline
calcification mass was correlated with change in calcification
mass, we excluded participants with no calcification at baseline
and with a calcification mass score >1000 (arbitrarily chosen) in
post-hoc analyses.
All measurements and analyses were performed blinded to
treatment. There were no missing data for the imaging, the
outcome measurement of interest. In the adjusted models, 2
participants had missing information on phylloquinone intake,
and median phylloquinone intake was imputed. Analyses were
performed with R version 3.2.2, and P < 0.05 was considered
statistically significant.
Results
A total of 108 patients were screened for participation in
this study; 40 patients were ineligible, mainly because of the
absence of CVD or because they declined to participate (Figure
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FIGURE 1 Flowchart of study participation. CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.
7 group and 33 to the placebo group. Eight patients were
lost to follow-up (MK-7 group: 2; placebo group: 6). Reasons
for loss to follow-up were unrelated to the intervention and
mainly due to technical problems during the first PET/CT
acquisition.
Baseline characteristics are shown in Table 1. The study
included 16 women (24%), and the mean age was 69.1 y
(SD = 8.4). Participants in the MK-7 group had higher baseline
calcification levels, higher phylloquinone intake, and more
often a low ABI compared with the placebo group. Baseline
characteristics of participants with a complete follow-up were
comparable to those of the randomly assigned participants
(Supplemental Table 1).
The absolute differences between baseline and 6-mo inter-
vention are presented in Figure 2. After 6-mo intervention,
TBR tended to increase, with 0.25 in the MK-7 group (95%
CI: –0.02, 0.51; P = 0.06) compared with placebo. Log-
transformed calcification mass did not increase in the MK-
7 group compared with placebo (0.50; 95% CI: −0.24, 1.23;
P = 0.18), although this result was not statistically significant
(Table 2). Adjustment for baseline characteristics (baseline
calcification mass, phylloquinone intake, and low ABI) did not
alter these results.
TBR and calcification mass were modestly correlated at
baseline (r = 0.47; 95% CI: 0.27, 0.64). Furthermore, baseline
calcification mass was modestly correlated with change in
calcification mass between baseline and 6 mo (r = 0.53; 95%
CI: 0.32, 0.69), whereas TBR at baseline was not correlated with
change in TBR levels during follow-up (r = −0.01; 95% CI:
−0.35, 0.15). Finally, change in TBR was not correlated with
change in calcification mass (r = 0.14; 95% CI: −0.12, 0.38).
Based on the correlation between calcification at baseline and
change in calcification mass, we excluded participants with no
calcification at baseline (n= 3), which resulted in a similar effect
of MK-7 compared with placebo on TBR for 6-mo intervention
(Table 2), whereas calcification mass significantly increased
(model 1: 0.22; 95% CI: 0.04, 0.41; P = 0.02). When excluding
participants with a high calcification mass at baseline (n= 3), the
results were similar to those in the full study population for both
TBR and calcification mass.
MK-7 supplementation significantly reduced inactive MGP
concentrations after 3 mo of intervention compared with placebo
(−205.6 pmol/L; 95% CI: −255.8, −155.3 pmol/L; P < 0.01)
(Figure 3). This effect of MK-7 compared with placebo was
sustained after 6 mo (−202.7 pmol/L; 95% CI: −272.5, −132.8
pmol/L; P< 0.01), indicating high compliance. According to pill
count, compliance was also high: 97.4% (95%CI: 92.3%, 99.1%)
in the intervention group and 97.8% (95% CI: 94.2%, 99.7%) in
the placebo group. No serious adverse events were reported.
Discussion
In contrast to our hypothesis, active vascular calcification
on 18F-NaF PET scan tended to increase after MK-7 supple-
mentation compared with placebo during 6-mo intervention. In
addition, no effect of MK-7 supplementation on CT calcification
mass was found. Therefore, this study does not support thatMK-7
supplementation inhibits vascular calcification.
This study has several strengths. First, it is a randomized,
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TABLE 1 Baseline characteristics of all randomly assigned participants
Characteristics Vitamin K (n = 35)1 Placebo (n = 33)1
Age, y 69.1 ± 8.4 69.1 ± 8.4
Women, n 9 (25.7) 7 (21.2)
BMI, kg/m2 31.1 ± 5.6 31.1 ± 5.0
Systolic BP, mm Hg 136.0 ± 20.5 137.8 ± 14.3
Diastolic BP, mm Hg 69.8 ± 11.4 73.5 ± 9.5
Current smoker, n 6 (17.1) 4 (12.1)
Higher educated, n 15 (42.9) 13 (39.4)
Vitamin D supplements, n 23 (65.7) 24 (72.7)
ABI ≤ 0.9 16 (45.7) 9 (27.3)
Laboratory measurements
HbA1c, mmol/mol 57.1 ± 14.8 59.6 ± 17.1
eGFR, mL/min/1.73 m2 79.2 ± 26.2 86.6 ± 26.1
Total cholesterol, mmol/L 4.5 ± 1.3 4.2 ± 1.2
HDL cholesterol, mmol/L 1.1 ± 0.3 1.1 ± 0.3
LDL cholesterol, mmol/L 2.1 ± 0.9 2.0 ± 0.9
Triglycerides, mmol/L 2.8 (1.8–3.4) 1.9 (1.5–2.7)
dp-ucMGP, pmol/L 613 (513–684) 615 (489–743)
Energy-adjusted vitamin K intake
Total vitamin K, microgram 167 (138–288) 141 (117–193)
Phylloquinone, mg 124.8 (100–225) 94 (73–149)
Menaquinones, mg 49 (35–57) 48 (33–52)
Calcification measurements
TBR 2.2 ± 0.7 2.1 ± 0.6
CT calcification mass 196.0 (32.5–424.0) 44.9 (9.6–409.5)
1Values are means ± SDs, medians (IQRs), or n (%). ABI, ankle–brachial index; BP, blood pressure; CT, computed tomography; dp-ucMGP,
dephosphorylated–uncarboxylated matrix Gla protein; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; TBR, target-to-background
ratio.
and interobserver reliability for assessment of imaging. Second,
this is the first study to investigate the effect of MK-7
supplementation in patients with type 2 diabetes, who are known
to be prone to medial calcification (23). Finally, an innovative
measurement of vascular calcification was used as the primary
endpoint, allowing sensitive detection of changes in vascular
calcification activity (13). However, some limitations need to
be addressed, which might partially explain the unexpected
results. The dropout rate was relatively high, especially in
the placebo group. Although the reasons for dropout were
unrelated to treatment, it may have reduced power to detect the
effects of vitamin K supplementation. However, if we recalculate
FIGURE 2 Absolute changes in TBR (left) and calcification mass (CT; right) in the placebo and vitamin K group between baseline and 6-mo intervention,
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TABLE 2 Results of linear regression analyses and sensitivity analyses excluding participants without baseline calcification and with high baseline
calcification levels
Linear regression P value
TBR (n = 60)
Model 1 0.25 (−0.02, 0.51) 0.06
Model 2 0.31 (0.02, 0.60) 0.03
Sensitivity analyses 1 (n = 57)
Model 1 0.24 (−0.03, 0.52) 0.08
Model 2 0.32 (0.02, 0.62) 0.04
Sensitivity analyses 2 (n = 54)
Model 1 0.24 (−0.04, 0.52) 0.09
Model 2 0.34 (0.04, 0.64) 0.03
Calcification mass (n = 60)1
Model 1 0.50 (−0.24, 1.23) 0.18
Model 2 0.40 (−0.36, 1.16) 0.30
Sensitivity analyses 1 (n = 57)1
Model 1 0.22 (0.04, 0.41) 0.02
Model 2 0.27 (0.08, 0.47) <0.01
Sensitivity analyses 2 (n = 54)1
Model 1 0.42 (−0.32, 1.16) 0.26
Model 2 0.41 (−0.37, 1.19) 0.29
1Values are log-transformed values (95% CIs). Model 1: linear regression models included outcome measurement as the dependent variable, and
intervention and baseline measures were used as independent values. Model 2: additionally adjusted for calcification mass, phylloquinone intake, and
ankle–brachial index. Sensitivity analyses 1: exclusion of 3 participants with no baseline calcification mass (CT), n = 57. Sensitivity analyses 2: exclusion of
6 participants with baseline calcification mass score <1000 (CT), n = 54. CT, computed tomography; TBR, target-to-background ratio.
the sample size using the mean and SD of this study, the
study has the statistical power of 85% to detect changes in
vascular calcification despite the high dropout rate. Importantly,
the baseline characteristics of the subjects who completed
follow-up were comparable to those of all randomly assigned
participants, making selection bias unlikely. However, the
primary outcome parameter—that is, vascular calcification—was
unexpectedly higher in the vitamin K treatment group, despite
FIGURE 3 dp-ucMGP concentrations in the placebo and vitamin K group at baseline, 3 mo, and 6 mo intervention, including medians and IQRs. The
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randomization, which might have influenced the results. Finally,
our diabetes patient cohort did not show a severe vitamin K
deficiency.
A previous study investigating the effect of phylloquinone
supplementation on coronary artery calcification showed a
protective effect of vitamin K supplementation in older men and
women (8). In addition, a recent study in patients with aortic valve
calcification supplemented with vitamin K for 1 y found a 50%
inhibition of progression of vascular calcification (9). Our study
is the first to assess the effect of MK-7 on vascular calcification
measured by 18F-NaF activity. To date, the effect of MK-7 has
been studied only in association with arterial stiffness, which
showed a beneficial effect of MK-7 supplementation on pulse
wave velocity (10, 11). Only 1 study did not detect an effect of
MK-7 supplementation on arterial stiffness and physical function
during 6-mo follow-up, which was probably due to the low-
dose MK-7 supplementation (100 μg) and relative short follow-
up period to detect changes in arterial stiffness (12). The MK-7
dosage in our study was much higher than that in the previously
mentioned trial. The follow-up period in our study was similar
to that of the previous study, but because 18F-NaF PET scan is
designed to detect early changes in calcification, it is not likely
that the follow-up period explains our results.
Based on the previously mentioned studies, we hypothesized
that MK-7 supplementation would hold vascular calcification
progression, resulting in lower 18F-NaF PET activity. Contrary to
our hypothesis, 18F-NaF activity tended to increase in the MK-7
group compared with the placebo group, although these results
lacked statistical significance. One reason for this unexpected
result might be the difference in calcification mass at baseline,
which was higher in the MK-7 group than in the placebo
group, despite randomization. Previous studies on determinants
of coronary artery calcification (CAC) progression showed that
a high baseline CAC burden was the strongest predictor of CAC
progression (21, 22). In line with this, in our study a high baseline
calcification mass was correlated with an increase in calcification
mass during follow-up. Because calcification mass was higher
in the MK-7 group at baseline, this may explain the higher
progression of vascular calcification in this group compared with
the placebo group. However, excluding participants with high
baseline calcification mass only slightly attenuated the effect of
MK-7 supplementation on change in calcificationmass compared
with placebo and did not alter our results for TBR.
Another explanation for these results may concern the
interpretation of 18F-NaF PET activity as a marker of active
calcification. 18F-NaF PET activity is promising to detect
early changes in active deposition of vascular calcification
probably before calcifications become visible on CT, due to
the binding of the tracer to hydroxyapatite, thereby enabling
the detection of microcalcifications (24). Our study is the
second trial using 18F-NaF PET activity for treatment follow-
up. One previous trial investigating the effect of etidronate on
vascular calcification in patients with pseudoxanthoma elasticum
found no effect on 18F-NaF PET activity in the femoral artery,
whereas CT images showed a significant reduction of vascular
calcification in the intervention group (25). This challenges our
understanding of what 18F-NaF PET activity in femoral arteries
actually represents. In addition, in some studies, some areas of
macrocalcification showed no 18F-NaF uptake, whereas other
areas with microcalcification showed high 18F-NaF uptake (26).
Macrocalcifications have a larger volume but a small surface area,
whereas microcalcifications have a large surface area. Because
18F-NaF is only incorporated into the outer surface, our results
might reveal a shift from macro- to microcalcification with MK-
7 supplementation, by which 18F-NaF uptake increases as seen
in our results (26). In our study, changes in 18F-NaF PET activity
were directionally concordant with changes in calcification mass;
therefore, this does not fully explain our results. Currently,
multiple studies are investigating whether 18F-NaF PET activity
can identify the vulnerable atherosclerotic plaque, which might
shed light on the interpretation of our study results.
Finally, our hypothesis could be influenced by the absence of
a severe vitamin K deficiency in patients with type 2 diabetes,
although the dp-ucMGP concentrations in this study showed
some evidence of low vitamin K concentrations because dp-
ucMGP >300 pmol/L is considered to be in the normal healthy
range. Vitamin K deficiency has been shown to be a major
contributor to vascular calcification in other patients groups with
more severe deficiencies, such as chronic kidney disease patients.
Results of ongoing clinical trials studying the effect of MK-7 on
vascular calcification in these patient populations are awaited.
In conclusion, vitamin K supplementation tended to increase
18F-NaF activity compared with placebo and did not hold or
reduce active calcification. In addition, the use of vitamin
K supplementation did not reduce progression of vascular
calcification as measured by conventional CT. Results of ongoing
trials with vitamin K supplementation and further research
investigating the interpretation of 18F-NaF PET activity coupled
with higher-resolution imaging are needed to fully understand the
effects of vitamin K on vascular calcification.
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